The third drug has remained a black box — until now. Pfizer plans to block the activity ... analyst David Risinger said in a client note. Comirnaty, the Covid vaccine developed with BioNTech ...

United States health authorities Monday gave full approval to the COVID-19 vaccine developed by Pfizer-BioNTech, which will now be marketed under the Comirnaty brand. Moderna's drug is expected to ...

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Revenue for Q2 2024 was $13.3 billion, compared to $13.0 billion in Q2 2023. Revenues from Comirnaty, Pfizer's COVID-19 vaccine, experienced an 87% operational decline to $195 million. Conversely ...

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

The pharmaceutical company Pfizer Friday filed an application before Brazil's National Health Surveillance Agency (Anvisa) for its COVID-19 vaccine named Comirnaty to be cleared for use on ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...